Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63

NCT00369031 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped Safety issues

Conditions

HIV Infections

Interventions

BIOLOGICAL: Human Immunodeficiency Virus glycoprotein 140 (vaccine)
BIOLOGICAL: HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant
BIOLOGICAL: Labile Toxin mutant LTK63 adjuvant

Sponsor

St George's, University of London

Collaborators

[object Object]
[object Object]
[object Object]